Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2015-A00667-42 | Other Identifier | ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
PanCareLIFE Study is a cohort study of patients treated for cancer in childhood, and biological case-control study nested in the cohort (WP4) is coordinated by Erasmus MC-Sophia Children's Hospital in Holland.
Ensure optimal patient quality of life throughout his life is a priority for the research teams. PanCareLIFE Study also aims to identify the factors that predispose to impaired quality of life. It is in this light that will be offered to patients a quality of life questionnaires during the period of treatment and then periodically during long-term follow-up.
PanCareLIFE Study is a cohort study of patients treated for cancer in childhood, and biological case-control study nested in the cohort (WP4) is coordinated by Erasmus MC-Sophia Children's Hospital in Holland. At European level, approximately 1,200 women are expected in this latest study, the patients were already identified through certain regional or national registries in terms of cumulative doses of chemotherapy, surgery, radiation.
Ensure optimal patient quality of life throughout his life is a priority for the research teams. PanCareLIFE Study also aims to identify the factors that predispose to impaired quality of life. It is in this light that will be offered to former patients to complete quality of life questionnaires during the period of treatment and then periodically during long-term follow-up.
The SALTO-BIO study is the French part of the European study PanCareLIFE. CHU of Saint-Etienne as French promotor, will organize this study only on the Rhône-Alpes region (Lyon, Grenoble and Saint-Etienne centers) and will participate as co-investigator and "data provider "to WP2, WP3, WP4 and WP6. Indeed, ototoxicity is already studied by a French group.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pediatric cancer women survivors | Women diagnosed for a cancer between 01/01/87 and 31/12/99 before the age of 15 years old living in Rhône-Alpes, will incur a blood taking for DNA tests (hormone tests) to see their fertility capacity. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pediatric cancer women survivors | Other | Women will incur a blood taking to obtain fertility indication. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Measure the FSH hormone rate. | In this arm women will incur a blood taking to measure the FSH hormone rate. | Day 1 |
| Measure the AMH hormone rate. | In this arm women will incur a blood taking to measure the AMH hormone rate. | Day 1 |
| Detect the genetic polymorphism of the FSH and AMH hormones. | With the blood taking realized for each patient, genetic markers will be obtained to identify their fertility capacity. | Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of life | The quality of life for each patient will be measured with the SF-36 scale. | Day 1 |
| Identification of new loci associated to ovarian toxicity | With a pan-genomic method, new loci (associated to ovarian toxicity) will be identified. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- severe mental disorder
Not provided
Not provided
Not provided
The population studied belongs to a cohort composed of women treated for a cancer in their childhood (diagnosed between 1987 and 1999 in Rhône-Alpes Region) before 15 years old.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| BERGER Claire, MD | Centre Hospitalier Universitaire de Saint Etienne | Principal Investigator |
| Léonie CASAGRANDA, PhD | Centre Hospitalier Universitaire de Saint Etienne | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chu Grenoble | Grenoble | 38000 | France | |||
| IHOP 1 Lyon |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
25 ml of blood for each patient will be necessary to measure the AMH and FSH hormones rates.
| Day 1 |
| Lyon |
| 69000 |
| France |
| CH Lyon Sud | Pierre-Bénite | 69000 | France |
| CHU Saint-Etienne | Saint-Etienne | 42000 | France |